Altre lingue Biomind Labs Inc.

Azioni

BMND.F

CA0907021012

Prezzo di chiusura OTC Markets Altri mercati azionari 00:00:00 04/04/2024			Variaz. 5gg	Var. 1 gen.
0,11 ^USD	0,00%		0,00%	+10,00%

2023	Biomind Labs completa lo sviluppo del primo schema di sintesi organica 5-MeO-DMT per applicazioni farmaceutiche	CI
2023	Biomind Labs Inc. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Canadian Investment Regulatory Organization Trading Halt - BMND	09/04
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	14/09/23
Biomind Labs Completes the Development of the First 5-MeO-DMT Organic Synthesis Scheme for Pharmaceutical Applications	14/09/23
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	16/05/23
An unknown buyer acquired 27.09% stake in Biomind Labs Inc. (OTCPK:BMND.F) from Union Acquisition Group, LLC for $14.1 million.	27/04/23
Biomind Labs Inc. Announces the Start of the First-Ever Clinical Trial Targeting Depression and Anxiety in Alzheimer’S Disease with A Proprietary Formulation Based on 5-Meo-Dmt	25/04/23
Biomind Labs Inc. Auditor Raises 'Going Concern' Doubt	31/03/23
Biomind Labs Announces the Completion of the First Sublingual Formulation for Its BMND08 Candidate for Depression and Anxiety in Alzheimer's Disease	29/12/22
Biomind Labs Inc. Announces the Completion of the First Sublingual Psychedelic Formulation for Its Drug Candidate Bmnd08 for Depression and Anxiety in Alzheimer’s Disease	28/12/22
Biomind Labs Inc. Announces FDA Investigational New Drug Clearance for its New Chemical Entity Triptax™ Targeting Treatment-Resistant Depression	15/11/22
Biomind Labs Inc. Announces Positive Initial Results From Its Phase II Trial on its BMND01 Candidate for Treatment Resistant Depression	04/11/22
Biomind Labs Announces Pre-Ind Meeting Request Granted by FDA for Its New Chemical Entity Triptax Targeting Treatment-Resistant Depression	11/10/22
Biomind and Queen's University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System	28/09/22
Biomind Labs and Queen's University of Belfast Receives Controlled Substances License to Commence the Production of A Novel Transdermal Drug Delivery System	27/09/22
Biomind Labs Announces Completion of Dosing in Phase II Trial of its DMT-Based Inhaled Formulation Bmnd01 for Treatment-Resistant Depression	21/09/22
Biomind Labs Inc. Receives Approval for A Third Phase II Clinical Trial for Its 5-Meo-Dmt Based Bmnd08 Candidate for Treatment of Depression and Anxiety in Alzheimer’s Disease	26/05/22
Crosswinds Holdings Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22
Biomind Labs Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	16/05/22
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression	26/04/22
Biomind Labs Doses First Subject in Phase I/IIa Clinical Trial of Its DMT-Based Inhaled Formulation BMND01 for Treatment-Resistant Depression	26/04/22

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Biomind Labs Inc.

Azioni

BMND.F

CA0907021012

Altre lingue

Filtri